Mien‐Chie Hung

99.5k total citations · 30 hit papers
745 papers, 67.2k citations indexed

About

Mien‐Chie Hung is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mien‐Chie Hung has authored 745 papers receiving a total of 67.2k indexed citations (citations by other indexed papers that have themselves been cited), including 463 papers in Molecular Biology, 338 papers in Oncology and 125 papers in Cancer Research. Recurrent topics in Mien‐Chie Hung's work include HER2/EGFR in Cancer Research (123 papers), Monoclonal and Polyclonal Antibodies Research (87 papers) and Cancer-related Molecular Pathways (80 papers). Mien‐Chie Hung is often cited by papers focused on HER2/EGFR in Cancer Research (123 papers), Monoclonal and Polyclonal Antibodies Research (87 papers) and Cancer-related Molecular Pathways (80 papers). Mien‐Chie Hung collaborates with scholars based in United States, Taiwan and China. Mien‐Chie Hung's co-authors include Weiya Xia, Dihua Yu, Binhua P. Zhou, Gabriel N. Hortobágyi, Robert A. Weinberg, Hirohito Yamaguchi, Cornelia I. Bargmann, Yongkun Wei, Jung-Mao Hsu and Yong Liao and has published in prestigious journals such as Nature, Science and Cell.

In The Last Decade

Mien‐Chie Hung

736 papers receiving 66.3k citations

Hit Papers

PTEN activation contributes to tumor inhibition... 1986 2026 1999 2012 2004 2004 1995 1986 2001 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
    2004 1.4k citations Francisco J. Esteva, Mien‐Chie Hung et al. profile →
  2. Dual regulation of Snail by GSK-3β-mediated phosphorylation in control of epithelial–mesenchymal transition
    2004 1.3k citations Binhua P. Zhou, Weiya Xia et al. profile →
  3. Requirement for neuregulin receptor erbB2 in neural and cardiac development
    1995 1.0k citations Mien‐Chie Hung et al. profile →
  4. The neu oncogene encodes an epidermal growth factor receptor-related protein
    1986 965 citations Mien‐Chie Hung et al. profile →
  5. Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells
    2001 915 citations Binhua P. Zhou, Weiya Xia et al. profile →
  6. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185
    1986 867 citations Mien‐Chie Hung et al. profile →
  7. Nuclear localization of EGF receptor and its potential new role as a transcription factor
    2001 863 citations Shiaw‐Yih Lin, Weiya Xia et al. profile →
  8. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression
    2017 768 citations Weiya Xia, Jung-Mao Hsu et al. profile →
  9. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation
    2001 749 citations Binhua P. Zhou, Weiya Xia et al. profile →
  10. BAP1 links metabolic regulation of ferroptosis to tumour suppression
    2018 743 citations Mien‐Chie Hung et al. profile →
  11. IκB Kinase Promotes Tumorigenesis through Inhibition of Forkhead FOXO3a
    2004 742 citations Mickey C.‐T. Hu, Weiya Xia et al. profile →
  12. Mechanisms Controlling PD-L1 Expression in Cancer
    2019 710 citations Li-Chuan Chan, Mien‐Chie Hung et al. profile →
  13. Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
    2006 696 citations Dihua Yu, Mien‐Chie Hung et al. profile →
  14. Metformin and Pathologic Complete Responses to Neoadjuvant Chemotherapy in Diabetic Patients With Breast Cancer
    2009 684 citations Mien‐Chie Hung et al. profile →
  15. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
    1997 679 citations Mien‐Chie Hung et al. PubMed profile →
  16. β-Catenin, a novel prognostic marker for breast cancer: Its roles in cyclin D1 expression and cancer progression
    2000 672 citations Shiaw‐Yih Lin, Weiya Xia et al. profile →
  17. Loss of FBP1 by Snail-Mediated Repression Provides Metabolic Advantages in Basal-like Breast Cancer
    2013 645 citations Mien‐Chie Hung, Binhua P. Zhou et al. profile →
  18. p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
    2011 606 citations Weiya Xia, Dihua Yu et al. profile →
  19. Long noncoding RNA MALAT1 suppresses breast cancer metastasis
    2018 546 citations Mien‐Chie Hung et al. profile →
  20. Generation and characterization of androgen receptor knockout (ARKO) mice: An in vivo model for the study of androgen functions in selective tissues
    2002 534 citations Mien‐Chie Hung et al. profile →
  21. Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene Expression
    2007 526 citations Weiya Xia, Mien‐Chie Hung et al. Cancer Research profile →
  22. Erk Associates with and Primes GSK-3β for Its Inactivation Resulting in Upregulation of β-Catenin
    2005 507 citations Weiya Xia, Mien‐Chie Hung et al. profile →
  23. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
    2021 405 citations Ri‐Yao Yang, Linlin Sun et al. Nature Communications profile →
  24. STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion
    2018 354 citations Jung-Mao Hsu, Weiya Xia et al. Nature Communications profile →
  25. Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
    2022 347 citations Jung-Mao Hsu, Mien‐Chie Hung et al. profile →
  26. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade
    2019 333 citations Mien‐Chie Hung et al. profile →
  27. The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis
    2020 260 citations Weiya Xia, Mien‐Chie Hung et al. profile →
  28. TYRO3 induces anti–PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis
    2021 255 citations Baozhen Ke, Jung-Mao Hsu et al. profile →
  29. Molecular mechanisms and functions of pyroptosis in inflammation and antitumor immunity
    2021 216 citations Jung-Mao Hsu, Mien‐Chie Hung et al. profile →
  30. Advances and prospects of biomarkers for immune checkpoint inhibitors
    2024 50 citations Jung-Mao Hsu, Linlin Sun et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mien‐Chie Hung United States 138 43.4k 28.0k 13.8k 8.4k 7.7k 745 67.2k
Carlos Cordon‐Cardo United States 129 41.4k 1.0× 22.8k 0.8× 12.8k 0.9× 7.1k 0.8× 11.0k 1.4× 564 68.1k
Lance A. Liotta United States 129 34.6k 0.8× 16.9k 0.6× 16.9k 1.2× 4.4k 0.5× 5.2k 0.7× 658 62.1k
Peter Carmeliet Belgium 151 53.1k 1.2× 15.0k 0.5× 27.4k 2.0× 11.7k 1.4× 9.1k 1.2× 729 100.0k
John D. Minna United States 140 42.2k 1.0× 26.3k 0.9× 13.3k 1.0× 8.8k 1.0× 14.7k 1.9× 803 73.8k
Axel Ullrich Germany 97 32.2k 0.7× 23.0k 0.8× 6.8k 0.5× 8.3k 1.0× 4.3k 0.6× 257 55.6k
David P. Lane United Kingdom 124 37.4k 0.9× 32.2k 1.2× 8.7k 0.6× 3.7k 0.4× 4.2k 0.5× 620 57.7k
Darell D. Bigner United States 103 22.1k 0.5× 15.6k 0.6× 10.4k 0.8× 8.3k 1.0× 6.5k 0.8× 623 48.1k
Webster K. Cavenee United States 99 31.7k 0.7× 12.7k 0.5× 13.7k 1.0× 4.6k 0.5× 8.8k 1.1× 315 62.0k
Judah Folkman United States 141 62.8k 1.4× 24.5k 0.9× 29.5k 2.1× 8.3k 1.0× 10.9k 1.4× 395 105.2k
Lisa M. Coussens United States 81 23.6k 0.5× 27.4k 1.0× 12.5k 0.9× 21.6k 2.6× 6.3k 0.8× 198 61.3k

Countries citing papers authored by Mien‐Chie Hung

Since Specialization
Citations

This map shows the geographic impact of Mien‐Chie Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mien‐Chie Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mien‐Chie Hung more than expected).

Fields of papers citing papers by Mien‐Chie Hung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mien‐Chie Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mien‐Chie Hung. The network helps show where Mien‐Chie Hung may publish in the future.

Co-authorship network of co-authors of Mien‐Chie Hung

This figure shows the co-authorship network connecting the top 25 collaborators of Mien‐Chie Hung. A scholar is included among the top collaborators of Mien‐Chie Hung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mien‐Chie Hung. Mien‐Chie Hung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Wei‐Jan, Wan‐Jou Shen, Chung‐Yu Chen, et al.. (2024). Novel SARS-CoV-2 inhibition properties of the anti-cancer Kang Guan Recipe herbal formula. Cancer Letters. 604. 217198–217198.
2.
Sun, Xian Wen, Wei‐Jan Wang, Ri‐Yao Yang, et al.. (2023). Inhibition of Galectin-9 sensitizes tumors to anthracycline treatment via inducing antitumor immunity. International Journal of Biological Sciences. 19(14). 4644–4656. 8 indexed citations
3.
Liu, Hong, et al.. (2023). Immune checkpoint blockades therapy of melanoma. Science Bulletin. 68(4). 356–358. 4 indexed citations
4.
Su, Wen‐Chi, King-Song Jeng, Yu‐Chi Chou, et al.. (2023). Functional assessments of SARS-CoV-2 single-round infectious particles with variant-specific spike proteins on infectivity, drug sensitivity, and antibody neutralization. Antiviral Research. 220. 105744–105744. 4 indexed citations
5.
Zheng, Fei-Meng, Caifeng Yue, Guohui Li, et al.. (2016). Nuclear AURKA acquires kinase-independent transactivating function to enhance breast cancer stem cell phenotype. Nature Communications. 7(1). 10180–10180. 146 indexed citations
6.
Chang, Yi-Wen, Mien‐Chie Hung, & Jen-Liang Su. (2014). The Anti-Tumor Activity of E1A and its Implications in Cancer Therapy. Archivum Immunologiae et Therapiae Experimentalis. 62(3). 195–204. 13 indexed citations
7.
Itamochi, Hiroaki, Linda X.H. Yuan, Francisco J. Esteva, et al.. (2005). Bcl-2 Antisense Oligonucleotide Overcomes Resistance toE1AGene Therapy in a Low HER2-Expressing Ovarian Cancer Xenograft Model. Cancer Research. 65(18). 8406–8413. 18 indexed citations
8.
Chen, Jin‐Shing, Keng‐Hsin Lan, & Mien‐Chie Hung. (2003). Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates. 6(3). 129–136. 70 indexed citations
9.
Tari, Ana M., Soo-Jeong Lim, Mien‐Chie Hung, Francisco J. Esteva, & Gabriel Lopez‐Berestein. (2002). Her2/neu induces all-transretinoic acid (ATRA) resistance in breast cancer cells. Oncogene. 21(34). 5224–5232. 63 indexed citations
10.
Yu, Dihua & Mien‐Chie Hung. (2000). Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene. 19(53). 6115–6121. 345 indexed citations
11.
Zhou, Binhua P., Mickey C.‐T. Hu, Stephanie A. Miller, et al.. (2000). HER-2/neu Blocks Tumor Necrosis Factor-induced Apoptosis via the Akt/NF-κB Pathway. Journal of Biological Chemistry. 275(11). 8027–8031. 322 indexed citations
12.
Zhou, Binhua P., et al.. (2000). Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27. Journal of Biological Chemistry. 275(32). 24735–24739. 109 indexed citations
13.
Xia, Weiya, et al.. (1999). Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members.. PubMed. 5(12). 4164–74. 246 indexed citations
14.
Li, Kaiyi, Ruping Shao, & Mien‐Chie Hung. (1999). Collagen-homology domain 1 deletion mutant of Shc suppresses transformation mediated by neu through a MAPK-independent pathway. Oncogene. 18(16). 2617–2626. 6 indexed citations
15.
Chen, Hua & Mien‐Chie Hung. (1997). Involvement of Co-activator p300 in the Transcriptional Regulation of the HER-2/neu Gene. Journal of Biological Chemistry. 272(10). 6101–6104. 39 indexed citations
16.
Chen, Hua, Dihua Yu, G. Chinnadurai, Devarajan Karunagaran, & Mien‐Chie Hung. (1997). Mapping of adenovirus 5 E1A domains responsible for suppression of neu-mediated transformation via transcriptional repression of neu. Oncogene. 14(16). 1965–1971. 19 indexed citations
17.
Zhang, Lisha, Ching‐Jer Chang, Sarah Bacus, & Mien‐Chie Hung. (1995). Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.. PubMed. 55(17). 3890–6. 147 indexed citations
18.
Matin, Angabin & Mien‐Chie Hung. (1993). Negative regulation of the neu promoter by the SV40 large T antigen.. PubMed. 4(12). 1051–6. 18 indexed citations
19.
Hung, Mien‐Chie, et al.. (1992). Aberrant expression of the c-erbB-2/neu protooncogene in ovarian cancer. Cancer Letters. 61(2). 95–103. 68 indexed citations
20.
Zhang, X., et al.. (1989). Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract.. PubMed. 4(8). 985–9. 92 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Carlos Cordon‐Cardo Breakdown of academic impact, for papers by Lance A. Liotta Breakdown of academic impact, for papers by Peter Carmeliet Breakdown of academic impact, for papers by John D. Minna Breakdown of academic impact, for papers by Axel Ullrich Breakdown of academic impact, for papers by David P. Lane Breakdown of academic impact, for papers by Darell D. Bigner Breakdown of academic impact, for papers by Webster K. Cavenee Breakdown of academic impact, for papers by Judah Folkman Breakdown of academic impact, for papers by Lisa M. Coussens
Rankless by CCL
2026